Sinovac Biotech, Chinese pharmaceutical company, launched the Phase III clinical trial of its Covid-19 vaccine on a group of children and teenagers between six months and 17 years old in South Africa.
Chinese Company is doing this study with South African company Numolux Group and has
enrolled approximately 2,000 participants in the country.
The participants shall receive two doses of Sinovac’s Corona vaccine or a placebo with 28 days gap.
The efficacy assessment will be based on relevant indicators, the Xinhua news agency reported.
The South African Health Products Regulatory Authority authorised the use of the CoronaVac vaccine on the country’s adults in July.